Gamida Cell: Positive Secondary Endpoints Topline Data from Omidubicel’s Phase 3 Trial in Hematologic Malignancies – CBI
Homepage /  Press Release /  Gamida Cell: Positive Secondary Endpoints Topline Data from Omidubicel’s Phase 3 Trial in Hematologic Malignancies

Press Release

Gamida Cell: Positive Secondary Endpoints Topline Data from Omidubicel’s Phase 3 Trial in Hematologic Malignancies